Press Releases April 22, 2026 07:30 AM

Arq Schedules First Quarter 2026 Earnings Conference Call

Arq, Inc. schedules Q1 2026 earnings call for May 7, reporting financial results and operational updates.

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
ARQ

Arq, Inc., a U.S. producer of activated carbon and environmentally efficient carbon products, announced it will release its first quarter 2026 financial results on May 6, followed by an earnings conference call on May 7. The company is the only vertically integrated activated carbon producer in North America, focusing on environmental technology solutions to purify water, land, and air.

Arq Schedules First Quarter 2026 Earnings Conference Call
ARQ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Arq will release Q1 2026 financial results and file Form 10-Q on May 6, 2026.
  • An earnings conference call is scheduled for May 7, 2026, to discuss financial performance.
  • Arq is the only vertically integrated activated carbon producer in North America, supplying products that remove harmful chemicals and pollutants.
  • The company's products support environmental technology sectors focusing on sustainability and pollution mitigation.

GREENWOOD VILLAGE, Colo., April 22, 2026 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced the Company will release its first quarter 2026 financial results and file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 after market close on Wednesday, May 6, 2026. A conference call to discuss the Company's financial performance is scheduled for Thursday, May 7, 2026 at 8:30 a.m. Eastern Time.

The conference call webcast information will be available via the Investor Resources section of Arq's website at www.arq.com. Interested parties may participate in the conference call by registering at https://www.webcast-eqs.com/arq2026q1. Alternatively, the live conference call may be accessed by dialing (800) 431-2204 or +1 (438) 792-9840 and referencing Arq.

A supplemental investor presentation will be available on the Company's Investor Resources section of the website prior to the start of the conference call.

A replay of the event will be made available shortly after the event and accessible via the same webcast link referenced above. Alternatively, the replay may be accessed by dialing (877) 660-6853 or (201) 612-7415 and entering Access ID 13760084. The dial-in replay will expire after May 14, 2026.

About Arq

Arq (NASDAQ: ARQ) is a diversified, environmental technology company with products that enable a cleaner and safer planet while actively reducing our environmental impact. As the only vertically integrated producer of activated carbon products in North America, we deliver a reliable domestic supply of innovative, hard-to-source, high-demand products. We apply our extensive expertise to develop groundbreaking solutions to remove harmful chemicals and pollutants from water, land and air. Learn more at: www.arq.com.

Source: Arq, Inc.

Investor Contact:

Anthony Nathan, Arq
Marc Silverberg, ICR
[email protected]


Risks

  • The announcement is a routine earnings schedule without new business or guidance updates, possibly limiting market impact.
  • Operational or financial results disclosed on May 6 may reveal risks related to demand, supply chain, or environmental regulations for activated carbon products.
  • Market volatility or macroeconomic factors could impact investor response despite the company's stable positioning.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026